Polyphyllin I Sensitizes Cisplatin-Resistant Human Cervical Cancer Cells to Cisplatin Treatment

References

• Bas S, Sijben J, Bischoff E, Bekkers RLM, de Kok I, Melchers WJG, Siebers AG, van der Waal D, Broeders MJM. Acceptability of risk-based triage in cervical cancer screening: a focus group study. PLoS One. 2023;18(8):e0289647. doi:10.1371/journal.pone.0289647
   PubMed Web of Science ®Google Scholar
• Omondi AA, Shaw-Ridley MD, Soliman A. Factors influencing cervical cancer screening among pregnant women in Nairobi, Kenya. Afr J Reprod Health. 2022;26(11):47–55. doi:10.29063/ajrh2022/v26i11.5
   PubMedGoogle Scholar
• Datta NR, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhüner A, Singh S, Bodis S. Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: a systematic review and meta-analysis. Gynecol Oncol. 2017;145(2):374–85. doi:10.1016/j.ygyno.2017.01.033.
   PubMed Web of Science ®Google Scholar
• Akpan MI, Ndep AO, Ekpenyong BN, Akpan IA, Akpan AI, Eyam LE, Ella RE, Ekanem EE. Cervical cancer screening services targeting adult women in Cross River State, Nigeria. Afr J Reprod Health. 2023;27:34–42.
   PubMed Web of Science ®Google Scholar
• Yang Y, Luan Y, Feng Q, Chen X, Qin B, Ren KD, Luan Y. Epigenetics and beyond: targeting histone methylation to treat type 2 diabetes mellitus. Front Pharmacol. 2021;12:807413. doi:10.3389/fphar.2021.807413
   PubMed Web of Science ®Google Scholar
• Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, Gray HJ, Goff BA, Shah CA, Neubauer NL. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. Eur J Gynaecol Oncol. 2023;44:17–25.
   PubMed Web of Science ®Google Scholar
• Chen CD, Dai LN, Wang M, Lai XH, Wang J. Hypoxia induces autophagy in PA-l ovarian teratoma cells and resistance to growth inhibition and apoptosis by chemotherapeutic agent cis-diamminedichloroplatinum. Eur J Gynaecol Oncol. 2017;38(2):277–81.
   PubMed Web of Science ®Google Scholar
• Eswaran S, Padavu M, Kumar D, Kabekkodu SP. Systematic analysis of the therapy resistance genes and their prognostic relevance in cervical cancer. Curr Pharm Des. 2023;29(25):2018–32. doi:10.2174/1381612829666230816100623
   PubMed Web of Science ®Google Scholar
• Sun AM, Wang YX, Hu GX, Li L, Wang RR. Polyphyllin I effects Candida albicans via inhibition of virulence factors. Evid Based Complement Alternat Med. 2023;2023:5645500. doi:10.1155/2023/5645500
   PubMed Web of Science ®Google Scholar
• Yuan L, Miao H, Ding H, Zhang F, Lou ZK, Li XG. Polyphyllin I suppressed the apoptosis of intervertebral disc nucleus pulposus cells induced by IL-1beta by miR-503-5p/Bcl-2 axis. J Orthop Surg Res. 2023;18(1):466. doi:10.1186/s13018-023-03947-7
   PubMed Web of Science ®Google Scholar
• Zheng F, Wang Y, Zhang Q, Chen Q, Liang CL, Liu H, Qiu F, Chen Y, Huang H, Lu W, et al. Polyphyllin I suppresses the gastric cancer growth by promoting cancer cell ferroptosis. Front Pharmacol. 2023;14:1145407. doi:10.3389/fphar.2023.1145407
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang X, An M. Polyphyllin I improves myocardial damage in coronary artery disease via modulating lipid metabolism and myocardial apoptosis. J Biochem Mol Toxicol. 2022;36(12):e23219. doi:10.1002/jbt.23219
   PubMed Web of Science ®Google Scholar
• Long J, Pi X. Polyphyllin I promoted melanoma cells autophagy and apoptosis via PI3K/Akt/mTOR signaling pathway. Biomed Res Int. 2020;2020:5149417. doi:10.1155/2020/5149417
   PubMed Web of Science ®Google Scholar
• Luo Q, Jia L, Huang C, Qi Q, Jahangir A, Xia Y, Liu W, Shi R, Tang L, Chen Z. Polyphyllin I promotes autophagic cell death and apoptosis of colon cancer cells via the ROS-inhibited AKT/mTOR pathway. Int J Mol Sci. 2022;23(16):23.
   Web of Science ®Google Scholar
• Lai L, Shen Q, Wang Y, Chen L, Lai J, Wu Z, Jiang H. Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling. Toxicol Appl Pharmacol. 2021;419:115518. doi:10.1016/j.taap.2021.115518
   PubMed Web of Science ®Google Scholar
• Feng F, Sun C, Wang X, Zhang H, Cheng P. Polyphyllin I induces apoptosis and autophagy in temozolomide-resistant glioma via modulation of NRF2 and MAPK-signaling activation. Biotechnol Genet Eng Rev. 2023;5:1–20. doi:10.1080/02648725.2023.2199553
   Google Scholar
• Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372–80. doi:10.1002/cncr.34974
   PubMed Web of Science ®Google Scholar
• Li C, Cang W, Gu Y, Chen L, Xiang Y. The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge. Front Immunol. 2023;14:1195476. doi:10.3389/fimmu.2023.1195476
   PubMed Web of Science ®Google Scholar
• Chen Z, Xiao Z, Tian W, Li Z, Wu T. Two enhances the cisplatin sensitivity of cervical cancer cells via suppression of c-MET expression. Iran J Public Health. 2023;52:1476–86.
   PubMed Web of Science ®Google Scholar
• Wu Y, Si Y, Xiang Y, Zhou T, Liu X, Wu M, Li W, Zhang T, Xiang K, Zhang L, et al. Polyphyllin I activates AMPK to suppress the growth of non-small-cell lung cancer via induction of autophagy. Arch Biochem Biophys. 2020;687:108285. doi:10.1016/j.abb.2020.108285
   PubMed Web of Science ®Google Scholar
• He J, Yu S, Guo C, Tan L, Song X, Wang M, Wu J, Long Y, Gong D, Zhang R, et al. Polyphyllin I induces autophagy and cell cycle arrest via inhibiting PDK1/Akt/mTOR signal and downregulating cyclin B1 in human gastric carcinoma HGC-27 cells. Biomed Pharmacother. 2019;117:109189. doi:10.1016/j.biopha.2019.109189
   PubMed Web of Science ®Google Scholar
• Dundr P, Hájková N, Kendall Bártů M, Cibula D, Drozenová J, Fabian P, Fadare O, Frühauf F, Hausnerová J, Hojný J, et al. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance. Pathology. 2023;55(6):785–91. doi:10.1016/j.pathol.2023.04.008
   PubMed Web of Science ®Google Scholar
• Duan J, Zhang Z, Du J, Zhang J, Li M, Li C. Esomeprazole alleviates cisplatin resistance by inhibiting the AKT/mTOR pathway in ovarian cancer cells. Onco Targets Ther. 2023;16:425–40. doi:10.2147/OTT.S406009
   PubMed Web of Science ®Google Scholar
• Wang D, Tang X, Ruan J, Zhu Z, Wang R, Weng Y, Zhang Y, Wang T, Huang Y, Wang H, et al. HSP90AB1 as the druggable target of maggot extract reverses cisplatin resistance in ovarian cancer. Oxid Med Cell Longev. 2023;2023:9335440–24. doi:10.1155/2023/9335440
   PubMedGoogle Scholar